Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'
Publication year
2017Source
Annals of Oncology, 28, 12, (2017), pp. 3000-3008ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Medical Oncology
Journal title
Annals of Oncology
Volume
vol. 28
Issue
iss. 12
Page start
p. 3000
Page end
p. 3008
Subject
All institutes and research themes of the Radboud University Medical Center; Radboudumc 9: Rare cancers RIHS: Radboud Institute for Health SciencesThis item appears in the following Collection(s)
- Academic publications [238441]
- Faculty of Medical Sciences [90373]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.